Low testosterone appears to increase long-term risk of death

Men may not live as long if they have low testosterone, regardless of their age, according to a new study. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.

The new study, from Germany, adds to the scientific evidence linking deficiency of this sex hormone with increased death from all causes over time—so-called "all-cause mortality."

The results should serve as a warning for men with low testosterone to have a healthier lifestyle, including weight control, regular exercise and a healthy diet, said lead author Robin Haring, a PhD student from Ernst-Moritz-Arndt University of Greifswald, Institute for Community Medicine.

"It is very possible that lifestyle determines levels of testosterone," he said.

In the study, Haring and co-workers looked at death from any cause in nearly 2,000 men aged 20 to 79 years who were living in northeast Germany and who participated in the Study of Health in Pomerania (SHIP). Follow-up averaged 7 years. At the beginning of the study, 5 percent of these men had low blood testosterone levels, defined as the lower end of the normal range for young adult men. The men with low testosterone were older, more obese, and had a greater prevalence of diabetes and high blood pressure, compared with men who had higher testosterone levels, Haring said.

Men with low testosterone levels had more than 2.5 times greater risk of dying during the next 10 years compared to men with higher testosterone, the study found. This difference was not explained by age, smoking, alcohol intake, level of physical activity, or increased waist circumference (a risk factor for diabetes and heart disease), Haring said.

In cause-specific death analyses, low testosterone predicted increased risk of death due to cardiovascular disease and cancer but not death of any other single cause.

Source: The Endocrine Society

Related stories:

How advanced prostate cancer becomes resistant to androgen-deprivation therapy
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone – the hormone that fuels prostate-cancer growth – via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
Celebrex-Lipitor combo may halt prostate cancer
Researchers at Rutgers’ Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.
Older men may not live as long if they have low testosterone
Low levels of testosterone may increase the long-term risk of death in men over 50 years old, according to researchers with the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine.
Sex hormones link to heart risk
Men are more prone to – and likely to die of - heart disease compared with women of a similar age – and sex hormones are to blame, according to a new University of Leicester led study.
Young type-2 diabetic men suffer low testosterone levels, study shows
Young men with type 2 diabetes have significantly low levels of testosterone, endocrinologists at the University at Buffalo have found -- a condition that could have a critical effect on their quality of life and on their ability to father children.
Testosterone and body fat are controlled by the same genes
Genes that control percentage of body fat are also responsible for circulating levels of testosterone in men, research published in the latest edition of Clinical Endocrinology shows. The research shows a 23% overlap between the genes that control testosterone and those that regulate body fat composition, suggesting that these two variables are partly controlled by the same set of genes.
Testosterone predominance increases prevalence of metabolic syndrome during menopause
As testosterone progressively dominates the hormonal milieu during the menopausal transition, the prevalence of metabolic syndrome increases according to a new study by researchers at Rush University Medical Center. The study suggests this may be a pathway by which cardiovascular disease increases during menopause. The study is published in the July 28 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Seasonal programmed brain cell death foiled in living birds
Neurons in brains of one songbird species equipped with a built-in suicide program that kicks in at the end of the breeding season have been kept alive for seven days in live birds by researchers trying to understand the role that steroid hormones play in the growth and maintenance of the neural song system.

News discussion:

Medicine & Health news